Shield Therapeutics to Present at the Biotech Showcase 2011

WOLLERAU, Switzerland, January 7, 2011 - Shield Holdings AG (Shield), the independent specialty
pharmaceutical company focused on the development and commercialisation of
late-stage hospital pharmaceuticals, today announces that Carl Sterritt,
Chief Executive Officer, will present at the Biotech Showcase Conference on
Wednesday 12 January, 2011 at 14:30 PST/ 22:30 GMT at the Parc 55 Wyndham
Union Square Hotel in San Francisco, California.

About the Biotech Showcase(TM) (Innovation - Opportunity -
Collaboration)

Now in its third year, Biotech Showcase(TM) will feature
corporate presentations by 195 innovative life science companies to an
audience of public and private investors, business development executives and
professional advisors who are interested in investment opportunities and
collaboration. The showcase takes place during the week of one of the most
important healthcare investor conferences which annually attracts thousands
of healthcare and life science business executives to San Francisco in a
venue located close to the center of action. Public and private investors are
always invited to attend the showcase on a complimentary basis. The Biotech
Showcase(TM) was co-founded by Demy-Colton Life Science Advisors and EBD
Group, two organizations that have a long and successful history building
programs that meet the needs of the life sciences industry. Visit our website
for more information: www.ebdgroup.com/bts/index.php.

About Shield

Shield, founded in 2008, is an independent specialty
pharmaceutical company focused on the development and commercialisation of
late-stage, mineral-derived hospital pharmaceuticals which address areas of
high unmet medical need. Shield is currently preparing to undertake a global
pivotal Phase III study of its lead asset, ST10-021, for the treatment of
iron deficiency anaemia associated with inflammatory bowel disease. The
Company is headquartered in Wollerau, Switzerland. For further information,
please visit www.shieldtherapeutics.com.

    For more information about Shield, please contact:

    M:Communications
    Mary-Jane Elliott / Emma Thompson / Nick Francis
    Tel +44(0)20-7920-2345
    E-mail: shield@mcomgroup.com

For more information about Shield, please contact: M:Communications, Mary-Jane Elliott / Emma Thompson / Nick Francis, Tel +44(0)20-7920-2345, E-mail: shield at mcomgroup.com